Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Could These 3 "Recession-Proof" Dividend Stocks Surge 100% by 2031?
11:23am, Monday, 29'th Dec 2025
Microsoft is a terrific growth stock with an excellent dividend program. Johnson & Johnson and Coca-Cola are both outstanding dividend payers.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. (“Halda”), a c
HBK Sorce Advisory LLC Sells 4,661 Shares of Johnson & Johnson $JNJ
05:21am, Monday, 29'th Dec 2025
HBK Sorce Advisory LLC decreased its position in shares of Johnson and Johnson (NYSE: JNJ) by 8.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commis
Johnson & Johnson (NYSE:JNJ) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
02:14am, Sunday, 28'th Dec 2025
Shares of Johnson and Johnson (NYSE: JNJ - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-seven brokerages that are presently covering the firm, MarketBeat reports
Market Today: Metals Rally; Nvidia-Groq Deal Lifts NVDA
05:36pm, Friday, 26'th Dec 2025
Stock News Metals surge as stocks hold near records: Gold and silver hit fresh records while major U.S. indexes closed little changed; mining shares including F
Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth?
09:26am, Friday, 26'th Dec 2025
JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.
Johnson & Johnson halts mid-stage trial of experimental eczema drug
08:13am, Friday, 26'th Dec 2025
Johnson & Johnson said on Friday it has discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis, after it failed to meet efficacy goals in a
Dogs of the Dow Beat the Market in 2025 — Here's the Smarter 4-Stock Play for 2026
09:50am, Thursday, 25'th Dec 2025
Keeping things simple when investing is often best, which is why buying an index fund can be the optimal strategy.
Coho Partners Ltd. Sells 133,505 Shares of Johnson & Johnson $JNJ
06:22am, Wednesday, 24'th Dec 2025
Coho Partners Ltd. reduced its stake in shares of Johnson and Johnson (NYSE: JNJ) by 43.3% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi
Baldwin Wealth Partners LLC MA Sells 3,828 Shares of Johnson & Johnson $JNJ
05:15am, Wednesday, 24'th Dec 2025
Baldwin Wealth Partners LLC MA reduced its holdings in Johnson and Johnson (NYSE: JNJ) by 5.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund o
BigSur Wealth Management LLC Lowers Stock Holdings in Johnson & Johnson $JNJ
05:15am, Wednesday, 24'th Dec 2025
BigSur Wealth Management LLC cut its stake in shares of Johnson and Johnson (NYSE: JNJ) by 33.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The
Johnson & Johnson Faces Legal Setback with $1.5 Billion Verdict
01:14pm, Tuesday, 23'rd Dec 2025
Johnson and Johnson (JNJ) confronts a new legal challenge after a $1.5 billion verdict was awarded to Cherie Craft, a Maryland woman who claimed the company's tal
Top 5 High-Yield S&P 500 Stocks to Buy for Reliable Returns in 2026
12:16pm, Tuesday, 23'rd Dec 2025
High-yield S&P 500 stocks IVZ, JNJ, NI, BG and MS offer steady income, compounding returns and portfolio stability as moderate growth and easing inflation shape 2026.
J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling
11:41am, Tuesday, 23'rd Dec 2025
The plaintiff's law firm said was the largest-ever sum awarded against J&J for a single plaintiff.
JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis
11:26am, Tuesday, 23'rd Dec 2025
Johnson & Johnson wins EU approval for Tremfya in pediatric plaque psoriasis, making it the first IL-23 inhibitor cleared for any pediatric condition.
